Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 13/20 | 0.69 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5687648 | 0.86 | LIPE (0.63) | LIPEBCHESCN9A | |
| SCHEMBL5689150 | 0.85 | LIPE (0.70) | LIPEBCHESCN9A | |
| SCHEMBL5931777 | 0.85 | LIPE (0.69) | LIPEBCHESCN9ACYP3A4GAA | |
| SCHEMBL5688548 | 0.82 | LIPE (0.66) | LIPEBCHESCN9A | |
| SCHEMBL5649993 | 0.82 | LIPE (1.00) | LIPEBCHESCN9ACYP3A4GAA | |
| SCHEMBL5690408 | 0.82 | LIPE (0.71) | LIPEBCHESCN9ACYP3A4GAA | |
| SCHEMBL5689964 | 0.82 | LIPE (0.67) | LIPEBCHESCN9AMAPTHTT | |
| SCHEMBL5688532 | 0.82 | LIPE (0.62) | LIPEBCHESCN9ACYP3A4GAA | |
| SCHEMBL5687908 | 0.81 | LIPE (0.68) | LIPEBCHECYP3A4GAAMAPT | |
| SCHEMBL5687747 | 0.80 | LIPE (0.60) | LIPEBCHESCN9AMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | LIPE 1/4885BCHE 32/4885SCN9A 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.